GSK Entered into a R&D Collaboration with LifeMine to Discover Novel Therapies for Multiple Disease
Shots:
- LifeMine to receive $70M up front including equity investment in its Series C round of financing & is also eligible to receive undisclosed discovery, development & commercial milestones along with royalties that emerge from the collaboration
- The companies will equally share costs to IND filing. GSK will be responsible for the development & commercialization of the product
- The collaboration will use LifeMine’s Avatar-Rx platform to identify novel small molecule leads directed to ~3 human targets that have been provided by GSK across multiple disease areas. LifeMine enables unparalleled speed, predictability & scalability to drug discovery & advance multiple-precision therapies
Ref: Businesswire | Image: GSK
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.